Navigation Links
Westaim announces 2009 third quarter results
Date:11/13/2009

TORONTO, Nov. 13 /PRNewswire-FirstCall/ - The Westaim Corporation announced today that for the quarter ended September 30, 2009, it recorded a net loss of $0.2 million, or zero cents per share, on revenues of $6.7 million compared to a net loss of $3.1 million, or 3 cents per share, on revenues of $5.5 million in the same quarter for the previous year.

The loss from continuing operations for the quarter ended September 30, 2009 was $0.02 million compared to a loss of $1.9 million for the same period in 2008.

For the nine months ended September 30, 2009, the Company posted revenues of $17.6 million and a net loss of $4.1 million or 4 cents per share. For the same period in 2008, Westaim reported revenues of $15.4 million and a net loss of $13.0 million, or 14 cents per share, which included the write-down of the capital assets and the termination of the operations of iFire Technology Ltd.

The loss from continuing operations for the nine months ended September 30, 2009 was $3.4 million compared to $0.5 million in the same period last year. The 2008 results benefited from a dilution gain of $6.0 million relating to the sale of a non-core subsidiary.

At September 30, 2009, Westaim had $38.6 million in consolidated cash and cash equivalents and $2.2 million in short-term investments compared to $39.1 million in consolidated cash and cash equivalents at September 30, 2008. Westaim's cash position, excluding cash and cash equivalents and short-term investments held by its 75 per cent owned subsidiary, NUCRYST Pharmaceuticals Corp., was $24.2 million.

Westaim recently announced the execution of an amalgamation agreement with NUCRYST Pharmaceuticals Corp. ( NCST; TSX: NCS). Under the agreement, NUCRYST has agreed to amalgamate with a newly-formed, wholly-owned subsidiary of Westaim with each holder of NUCRYST common shares (other than Westaim) to receive one redeemable preferred share in the capital of the a
'/>"/>

SOURCE Westaim Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Westaim announces 2009 second quarter results
2. Westaim announces 2009 first quarter results
3. Westaim enters into Management Services Agreement
4. Westaim announces 2008 year-end results
5. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
6. Westaim announces 2008 third quarter results
7. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2008 Third Quarter Results
8. Westaim terminates reorganization agreement and cancels shareholders meeting
9. Westaim to deregister its common stock in the United States
10. Westaim announces sale of iFire Technology Ltd. assets
11. Westaim announces 2008 second quarter results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... July 07, 2015 , ... ... communication management solutions, has announced the release of Service Pack 5600 for ... includes a number of enhancements to the already robust capabilities of the ...
(Date:7/7/2015)... ... July 07, 2015 , ... CareSync proudly announces ... recognized by the White House as a “Champion of Change” for Precision Medicine ... Initiative, the Champions of Change program recognizes Gleason and eight other extraordinary individuals ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... stages of drug discovery. iPSCs are generated from adult cells, such as blood ... cell type in the human body. , iPSC-derived cardiomyocytes have ...
(Date:7/6/2015)... ... July 06, 2015 , ... In order to ... American Orthopaedic Society for Sports Medicine ( AOSSM ) will present ten research ... As a leader in orthopaedic sports medicine, AOSSM annually provides more than ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... year for aesthetic reasons, which is why liposuction regularly ranks among the top ... however, fat reduction has become more than a way to slim down a ...
Breaking Medicine News(10 mins):Health News:ISI Telemanagement Solutions, Inc. Releases Service Pack 5600 for Infortel® Select 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 4Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 2Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 3Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 4Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 5Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 6Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3
... of the,nation,s largest providers of emergency department (ED) management ... in Berwyn,Ill., to run its ED starting Jan. 1, ... in 1975 by ED physicians driven to improve the ... CEP America focuses solely on,developing ED solutions for hospitals ...
... ASHP Midyear Clinical,Meeting and Exhibition -- Omnicell, ... provider of,system solutions to acute healthcare facilities, and ... Harvard Medical School located in,the heart ... the,planned installation of Omnicell,s SinglePointe(TM) automated patient-specific,medication management ...
... food costs, many,families are economizing on groceries but one ... about 25 cents per 8-ounce glass, on a gallon ... other beverage option in the,supermarket -- providing key vitamins ... for the entire family. To ensure moms don,t cut ...
... that Dr. Jonathan White will join the Company as head ... 8, 2008. In this role, Dr. White will have ... products to complement Haemonetics, blood management solutions portfolio. , ... CEO, said, "As the global leader in blood management solutions ...
... Maine, Dec. 8 IDEXX Laboratories, Inc. (Nasdaq: ... E. Brown, PhD as Corporate Vice President, Instrument Research ... Brown will oversee instrument development, manufacturing, and the worldwide ... "Bill,s extensive R&D and manufacturing management experience is distinctively ...
... Inc. (Nasdaq: HGSI ) today announced that it will sponsor ... 3 trial of Albuferon(R) (albinterferon alfa-2b) in chronic hepatitis C. , ... , The conference call will be hosted by ... 8:15 am Eastern Time. , , Investors ...
Cached Medicine News:Health News:CEP America Partners With MacNeal Hospital to Provide Emergency Department Management, Staffing 2Health News:Brigham and Women's Hospital Selects SinglePointe(TM) Automated Patient-Specific Medication Management Solution from Omnicell 2Health News:Brigham and Women's Hospital Selects SinglePointe(TM) Automated Patient-Specific Medication Management Solution from Omnicell 3Health News:Milk is One Beverage Jackson Can't Afford to Keep Off the Grocery List 2Health News:Milk is One Beverage Jackson Can't Afford to Keep Off the Grocery List 3Health News:Dr. Jonathan White Joins Haemonetics as Head of Research and Development 2Health News:IDEXX Laboratories Names William Brown Corporate Vice President 2Health News:Human Genome Sciences to Sponsor Conference Call 2
(Date:7/6/2015)... July 6, 2015 Array BioPharma,s (NASDAQ: ... this past weekend at the 2015 ESMO World ... At the meeting, data were shared from a ... 100-patient randomized Phase 2 expansion of that trial ... EGFR inhibitor, with or without the addition of ...
(Date:7/6/2015)... 6, 2015 Akcea Therapeutics, a wholly-owned ... ), announced today that the U.S. Food and ... volanesorsen (ISIS-APOCIII Rx ) for the treatment of ... a rare genetic disease characterized by extremely high ... Phase 2 study published in the NEJM in ...
(Date:7/4/2015)... BARCELONA , España, July 4, 2015 /PRNewswire/ ... SIR-Spheres® Y-90 a la quimioterapia de primera línea ... en el hígado (mCRC) extiende la supervivencia libre ... pacientes con cáncer colorrectal metastásico no resecable (mCRC) ... la mayor mejora en la supervivencia libre de ...
Breaking Medicine Technology:Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 2El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 3El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 4El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 5
... February 27 Novagali Pharma, a French,pharmaceutical ... first set of,data pertaining to Nova21027, its ... Novagali communicated about "Ocular ... conventional formulations of prostaglandin,analogues: an in vivo ...
... /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: ... of its new drug application ("NDA") for AFRESA(R), an ultra ... As previously announced, our internal goal was to submit the ... end of February. Based on editorial decisions made during ...
Cached Medicine Technology:Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma 2MannKind Updates Status of NDA Submission for AFRESA 2MannKind Updates Status of NDA Submission for AFRESA 3
... determination of Ang II is ... the pharmacological effect and efficiency ... angiotensin converting enzyme inhibitors (ACE ... antagonists as well as for ...
... antigen test is a visual ... presumptive qualitative detection of Respitory ... specimens in neonatal and pediatric ... test has a built-in procedural ...
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
... BD Directigen EZ RSV Test utilizes a new, ... one device for rapid RSV detection. The testing ... method whereby dried reagents have already been applied ... a two-step process, with clear-cut results shown by ...
Medicine Products: